Absci Corp. (ABSI)
NASDAQ:ABSI
Want to see ABSI full AI Analyst Report?
Top Page
AbSci
(NASDAQ:ABSI)
Select Model
Select Model
Rating:62Neutral
Price Target:
$10.50
▲(193.30% Upside)
Action:Reiterated
Date:06/25/26
ABSI scores in the low-60s primarily because strong technical momentum and a generally positive, catalyst-driven earnings outlook are tempered by weak financial fundamentals (large losses and heavy cash burn) and limited valuation support (negative earnings and no dividend).
Positive Factors
Fresh ~$100M equity offering
The June 2026 underwritten offering materially increases liquidity and meaningfully reduces near-term refinancing risk. Structural cash inflows support completion of planned clinical milestones and R&D programs, improving the firm’s ability to execute without immediate dependency on dilutive backstops.
Negative Factors
High cash burn
Substantial negative operating and free cash flow is a persistent structural weakness, creating recurring funding needs. Continued high burn requires repeated financing or milestone-dependent partner payments, constraining strategic optionality and increasing dilution or partnership dependence over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Fresh ~$100M equity offering
The June 2026 underwritten offering materially increases liquidity and meaningfully reduces near-term refinancing risk. Structural cash inflows support completion of planned clinical milestones and R&D programs, improving the firm’s ability to execute without immediate dependency on dilutive backstops.
Read all positive factors
AbSci (ABSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.16B
Dividend YieldN/A
Average Volume (3M)5.02M
Price to Earnings (P/E)―
Beta (1Y)2.47
Revenue Growth-61.87%
EPS Growth10.39%
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding155,905,060
10 Day Avg. Volume5,158,260
30 Day Avg. Volume5,023,345
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue607.40
Enterprise Value/Gross Profit-46.12
Enterprise Value/Ebitda-10.44
Forecast
1Y Price Target
$11.39Price Target Upside218.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$6.63M
AbSci Business Overview & Revenue Model
Company Description
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biol...
How the Company Makes Money
AbSci primarily makes money by providing drug discovery and development services to biopharmaceutical partners under collaboration agreements. Revenue is generally generated through (a) research and development service fees for conducting discover...
AbSci Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Positive
The call conveyed clear progress on the lead program (ABS-201) with favorable early safety/PK signals, supportive PK modeling for an infrequent dosing profile, a defined clinical timeline (interim 13-week readout in H2 2026 and full 26-week POC in early 2027), and a substantial addressable market supported by consumer and KOL research. The company expanded its prolactin-focused pipeline (ABS-202), sharpened strategic focus by de‑emphasizing oncology, and reported a cash runway into H1 2028. Offsetting these positives are a very small quarter revenue base ($200k), a cash decline of ~12.9% QoQ to $125.7M, increased R&D spend (+17.7% YoY), and remaining clinical and regulatory risks (directional 13-week readout, placebo risk in endometriosis). Overall, the call emphasized promising clinical and commercial potential but also highlighted near-term execution and financing sensitivities.Positive Updates
ABS-201 HEADLINE Trial Progressing On Track
Phase I/IIa HEADLINE trial tracking to plan: all 4 single ascending dose (SAD) cohorts dosed and first multiple ascending dose (MAD) cohort initiated. Emerging safety and tolerability data described as favorable, with blinded preliminary safety, tolerability and PK data expected next month. Interim 13-week directional hair regrowth readout planned for H2 2026 and full 26-week proof-of-concept (POC) readout expected early 2027.
Negative Updates
Minimal Near-Term Revenue
Revenue for the quarter was only $200,000, indicating limited near-term partnered revenue generation and continuing reliance on capital markets / partnerships for non-dilutive funding.
Read all updates
Q1-2026 Updates
Positive
Negative
ABS-201 HEADLINE Trial Progressing On Track
Phase I/IIa HEADLINE trial tracking to plan: all 4 single ascending dose (SAD) cohorts dosed and first multiple ascending dose (MAD) cohort initiated. Emerging safety and tolerability data described as favorable, with blinded preliminary safety, tolerability and PK data expected next month. Interim 13-week directional hair regrowth readout planned for H2 2026 and full 26-week proof-of-concept (POC) readout expected early 2027.
Read all positive updates
Company Guidance
Management provided a data‑rich roadmap: blinded preliminary safety, tolerability and PK data from the completed 4 SAD cohorts (with the first MAD cohort now dosing) will be shared next month, an interim 13‑week directional proof‑of‑concept hair‑regrowth readout is expected in H2 2026 and the full 26‑week POC readout in early 2027, with planned initiation of a Phase II endometriosis trial in Q4 2026 (subject to data/regulatory review) and the potential to advance directly to registrational trials; preliminary PK modeling supports a targeted dosing interval of 2–3 injections over 6 months (at least ~every 8 weeks) and a ~90% receptor‑occupancy goal. Market research tested a target product profile of 3 injections yielding ~35 hairs/cm2 and ~2.5 years of durability, supporting a U.S. AGA TAM >$25B and potential peak endometriosis sales >$4B (endometriosis prevalence up to 10% of women worldwide, ~9M in the U.S.), while consumer intent in surveys was high (87% of men, 69% of women overall; rising to 92%/89% among those already on standard‑of‑care). Financially, Q1 revenue was $200K, R&D expense $19.3M (vs $16.4M prior year), SG&A $9.1M (vs $9.5M), and cash, cash equivalents and marketable securities were $125.7M (down from $144.3M at 12/31/25), which management expects is sufficient to fund operations into the first half of 2028; strategic moves include adding ABS‑202, deprioritizing oncology programs ABS‑301/ABS‑501, pursuing partnerships and realizing efficiency gains from agentic AI.AbSci Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.84M | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M |
| Gross Profit | -24.18M | -8.94M | -57.92M | -41.85M | -53.16M | -39.80M |
| EBITDA | -106.83M | -103.16M | -94.10M | -79.68M | -91.36M | -67.68M |
| Net Income | -118.44M | -115.18M | -103.11M | -110.57M | -104.90M | -100.96M |
Balance Sheet | ||||||
| Total Assets | 195.59M | 216.30M | 213.61M | 217.30M | 321.01M | 426.19M |
| Cash, Cash Equivalents and Short-Term Investments | 125.70M | 144.29M | 112.42M | 97.66M | 164.43M | 252.57M |
| Total Debt | 4.42M | 5.30M | 10.11M | 15.88M | 22.98M | 20.01M |
| Total Liabilities | 23.62M | 26.85M | 34.48M | 41.12M | 46.59M | 60.09M |
| Stockholders Equity | 171.97M | 189.45M | 179.13M | 176.18M | 274.41M | 366.11M |
Cash Flow | ||||||
| Free Cash Flow | -98.50M | -94.03M | -72.81M | -65.50M | -97.51M | -98.64M |
| Operating Cash Flow | -97.39M | -92.92M | -72.40M | -64.64M | -81.34M | -60.60M |
| Investing Cash Flow | -27.75M | -50.16M | -41.58M | 81.94M | -126.98M | -67.38M |
| Financing Cash Flow | 70.71M | 105.95M | 82.53M | -4.48M | 5.24M | 336.19M |
AbSci Technical Analysis
Positive
3.58
Price Trends
5.62
Positive
4.20
Positive
3.80
Positive
Market Momentum
0.82
Negative
72.13
Negative
76.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABSI, the sentiment is Positive. The current price of 3.58 is below the 20-day moving average (MA) of 6.92, below the 50-day MA of 5.62, and below the 200-day MA of 3.80, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 72.13 is Negative, neither overbought nor oversold. The STOCH value of 76.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABSI.
AbSci Risk Analysis
AbSci disclosed 91 risk factors in its most recent earnings report. AbSci reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbSci Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $1.16B | -12.14 | -63.58% | ― | -61.87% | 10.39% | |
57 Neutral | $441.82M | -1.46 | -128.53% | ― | 928.46% | -21.39% | |
55 Neutral | $606.40M | -4.37 | -36.83% | ― | 383560.87% | 20.87% | |
52 Neutral | $858.16M | -11.48 | -33.07% | ― | ― | -20.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $146.27M | -1.02 | 65.27% | ― | 4.43% | 27.41% |
* Healthcare Sector Average
ABSI
AbSci
10.08
7.31
265.04%
AUTL
Autolus Therapeutics
1.59
-0.73
-31.47%
ADCT
ADC Therapeutics
1.07
-1.69
-61.23%
FDMT
4D Molecular Therapeutics
11.62
7.54
184.80%
DSGN
Design Therapeutics
13.78
9.83
248.86%
AbSci Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Absci Announces $100 Million Public Equity Offering
Positive
Jun 24, 2026
On June 24, 2026, Absci priced an underwritten public offering of 13,495,277 shares of common stock at $7.41 per share, for expected gross proceeds of about $100 million and estimated net proceeds of roughly $93.5 million. The deal, made under an ...
Business Operations and StrategyProduct-Related Announcements
Absci Reports Positive Phase 1 Data for ABS-201
Positive
Jun 24, 2026
On June 24, 2026, Absci reported positive interim Phase 1 data from its first-in-human HEADLINE trial of ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia. In 32 healthy adults given single ascending IV doses up to 1,800 mg, A...
Executive/Board ChangesShareholder Meetings
Absci Stockholders Approve Directors and Auditor at Meeting
Neutral
Jun 5, 2026
On June 4, 2026, Absci Corporation held its Annual Meeting of Stockholders, with 155,447,428 common shares eligible to vote as of the April 7, 2026 record date. Shareholders voted on board composition and audit oversight matters that shape the com...
Business Operations and StrategyFinancial Disclosures
Absci Advances ABS-201 Hair Loss Trial Amid Wider Loss
Neutral
May 7, 2026
Absci reported first-quarter 2026 results on May 7, 2026, highlighting progress on its AI-designed prolactin receptor pipeline and a widening operating loss as RD spending increased. Revenue for the quarter fell to $0.2 million from $1.2 million a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.